ANDA 218676, held by Quagen. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 218676 (Lidocaine Hydrochloride), held by Quagen, was first approved by FDA on Mar 20, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% ยท solution;oral | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters